EUVIMEDEUVIMED entdecken
Korrektur

Correction: Cannabidiol and its Potential Evidence-Based Psychiatric Benefits – A Critical Review

Inga Dammann, Cathrin Rohleder, F Markus Leweke iD

Pharmacopsychiatry · 01.05.2024 · 57 (03) · e2

DOI: 10.1055/a-2775-0902 ↗

Kurz gefasst

Korrektur in der Zeitschrift Pharmacopsychiatry, erschienen am 01.05.2024. Verfasst von Inga Dammann und 2 weiteren Autor:innen. Beteiligte Einrichtung: Dept. of Psychiatry and Psychotherapy, Central Institute of Mental Health, Mannheim, Germany.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Dept. of Psychiatry and Psychotherapy, Central Institute of Mental Health, Mannheim, Germany.
  • R&D, Endosane Pharmaceuticals GmbH, Berlin, Germany.
  • Brain and Mind Centre, Translational Research Collective, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.

ORCID-Profile: F Markus Leweke

Zitieren

APA

Dammann, I., Rohleder, C., & Leweke, F. M. (2024). Correction: Cannabidiol and its Potential Evidence-Based Psychiatric Benefits – A Critical Review. Pharmacopsychiatry, 57(03), e2. https://doi.org/10.1055/a-2775-0902

Vancouver

Dammann I, Rohleder C, Leweke FM. Correction: Cannabidiol and its Potential Evidence-Based Psychiatric Benefits – A Critical Review. Pharmacopsychiatry. 2024;57(03):e2. doi:10.1055/a-2775-0902

BibTeX
@article{Dammann2024,
  author = {Dammann, Inga and Rohleder, Cathrin and Leweke, F Markus},
  title = {Correction: Cannabidiol and its Potential Evidence-Based Psychiatric Benefits – A Critical Review},
  journal = {Pharmacopsychiatry},
  year = {2024},
  volume = {57},
  number = {03},
  pages = {e2},
  doi = {10.1055/a-2775-0902}
}
Kostenlos starten →